U.S. Markets closed

Complimentary Technical Snapshots on Prestige Brands and Three More Medical Equipment Stocks

Stock Research Monitor: EYES, SENS, and VAR

LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want a free Stock Review on PBH sign up now at www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com tracks the recent performance of Prestige Brands Holdings Inc. (NYSE: PBH), Second Sight Medical Products Inc. (NASDAQ: EYES), Senseonics Holdings Inc. (NYSE AMER: SENS), and Varian Medical Systems Inc. (NYSE: VAR). These companies operate in the Medical Appliances and Equipment space, which is engaged in the manufacture of medical instruments such as dental and surgical appliances. All you have to do is sign up today for this free limited time offer by clicking the link below.


Prestige Brands Holdings

Shares in Tarrytown, New York headquartered Prestige Brands Holdings Inc. saw a decline of 1.98%, ending Tuesday's trading session at $33.17. The stock recorded a trading volume of 1.04 million shares, which was higher than its three months average volume of 854,440 shares. The Company's shares have gained 9.47% in the last month. The stock is trading 1.01% above its 50-day moving average. Moreover, shares of Prestige Brands, which together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter healthcare and household cleaning products in North America, Australia, and internationally, have a Relative Strength Index (RSI) of 51.70.

On May 10th, 2018, Prestige Brands reported its results for its Q4 and fiscal year ended March 31st, 2018. For Q4 FY18, revenues were $256.0 million, gross profit margin was 55.2%, and net loss totaled $39.7 million. For the fiscal year 2018, revenues were $1.041 billion, gross profit margin was 55.4%, and net income totaled $339.6 million. Get the full research report on PBH for free by clicking below at:


Second Sight Medical Products

Sylmar, California headquartered Second Sight Medical Products Inc.'s stock jumped 5.31%, closing the day at $2.18 with a total trading volume of 263,201 shares. The Company's shares have surged 32.12% in the past month, 39.74% in the previous three months, and 91.23% over the past year. The stock is trading 20.20% and 41.34% above its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the US, Canada, Europe, Middle-East, and Asia, have an RSI of 63.49.

On May 14th, 2018, Second Sight Medical Products announced that Will McGuire, President and CEO, and John T. Blake, CFO, will present at the 19th Annual B. Riley FBR Investor Conference on May 24th, 2018, at 2:30 p.m. PT at Loews Santa Monica Beach Hotel. Access the free research report on EYES now by signing up at:


Senseonics Holdings

On Tuesday, shares in Germantown, Maryland headquartered Senseonics Holdings Inc. recorded a trading volume of 661,837 shares. The stock ended the day 1.20% lower at $3.30. The Company's shares have advanced 1.54% in the past month, 25.00% in the previous three months, and 134.04% over the past year. The stock is trading above its 50-day and 200-day moving averages by 1.90% and 13.04%, respectively. Furthermore, shares of Senseonics, which designs, develops, and commercializes continuous glucose monitoring systems for people with diabetes primarily in Europe, have an RSI of 55.27.

On May 10th, 2018, Senseonics reported its results for Q1 ended March 31st, 2018. Revenue was $2.9 million for the quarter, sales and marketing expenses were $3.4 million, and net loss was $22.3 million. As of March 30th, 2018, cash, cash equivalents, and marketable securities were $65.1 million and outstanding indebtedness was $75.5 million. Are you already registered with Wall St. Equities? Do so now for free, and get the report on SENS at:


Varian Medical Systems

Palo Alto, California headquartered Varian Medical Systems Inc.'s stock rose slightly by 0.02%, finishing yesterday's session at $118.81 with a total trading volume of 594,207 shares. The Company's shares have advanced 24.21% over the past year. The stock is trading above its 200-day moving average by 5.78%. Additionally, shares of the Company, which designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide, have an RSI of 49.68.

On May 07th, 2018, Varian Medical Systems (VAR) announced that it has acquired Cooperative CL Enterprises (COOP), a leading distributor of radiotherapy equipment in Taiwan. COOP currently employs 45 people and has represented VAR in Taiwan for more than 40 years. Aspiring Member, please take a moment to register below for your free research report on VAR at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities